Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Michael Lincoff

Showing results (91-100 of 353) with videos related to

Pageof 36
Sort By:
JAMA|October 23, 2003
Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classificationUmesh N Khot, Gang Jia, David J Moliterno, et al.
Obesity (Silver Spring, Md.)|June 23, 2025
Response to "Weight-loss drugs like Wegovy could lead to an increased risk of fragility fractures in population at risk"Robert F Kushner, Donna H Ryan, Nina M Harder-Lauridsen, et al.
The American Journal of Cardiology|February 22, 2005
Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial)Derek P Chew, A Michael Lincoff, Hitinder Gurm, et al.
Yonsei Medical Journal|April 24, 2002
Local delivery of nitric oxide from an eluting stent to inhibit neointimal thickening in a porcine coronary injury modelJung Han Yoon, Chiung Jen Wu, James Homme, et al.
The American Journal of Cardiology|April 13, 2002
Evidence that angiotensin-converting enzyme inhibitor use diminishes the need for coronary revascularization after stentingStephen G Ellis, A Michael Lincoff, Patrick L Whitlow, et al.
Circulation|February 6, 2002
Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different?K Martijn Akkerhuis, John H Alexander, Barbara E Tardiff, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|November 28, 2002
Reduction in vascular access site bleeding in sequential abciximab coronary intervention trialsJames C Blankenship, Craig Balog, Shelly K Sapp, et al.
Circulation|November 6, 2023
Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin IntolerancePaul M Ridker, Lei Lei, Michael J Louie, et al.
The American Journal of Cardiology|September 17, 2002
Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profileDean J Kereiakes, A Michael Lincoff, Keaven M Anderson, et al.
The Journal of Thoracic and Cardiovascular Surgery|March 7, 2006
A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON studyCornelius M Dyke, Nicholas G Smedira, Andreas Koster, et al.
Pageof 36

Showing results (91-100 of 353) with videos related to

Sort By:
Pageof 36
JAMA|October 23, 2003
Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classificationUmesh N Khot, Gang Jia, David J Moliterno, et al.
Obesity (Silver Spring, Md.)|June 23, 2025
Response to "Weight-loss drugs like Wegovy could lead to an increased risk of fragility fractures in population at risk"Robert F Kushner, Donna H Ryan, Nina M Harder-Lauridsen, et al.
The American Journal of Cardiology|February 22, 2005
Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial)Derek P Chew, A Michael Lincoff, Hitinder Gurm, et al.
Yonsei Medical Journal|April 24, 2002
Local delivery of nitric oxide from an eluting stent to inhibit neointimal thickening in a porcine coronary injury modelJung Han Yoon, Chiung Jen Wu, James Homme, et al.
The American Journal of Cardiology|April 13, 2002
Evidence that angiotensin-converting enzyme inhibitor use diminishes the need for coronary revascularization after stentingStephen G Ellis, A Michael Lincoff, Patrick L Whitlow, et al.
Circulation|February 6, 2002
Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different?K Martijn Akkerhuis, John H Alexander, Barbara E Tardiff, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|November 28, 2002
Reduction in vascular access site bleeding in sequential abciximab coronary intervention trialsJames C Blankenship, Craig Balog, Shelly K Sapp, et al.
Circulation|November 6, 2023
Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin IntolerancePaul M Ridker, Lei Lei, Michael J Louie, et al.
The American Journal of Cardiology|September 17, 2002
Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profileDean J Kereiakes, A Michael Lincoff, Keaven M Anderson, et al.
The Journal of Thoracic and Cardiovascular Surgery|March 7, 2006
A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON studyCornelius M Dyke, Nicholas G Smedira, Andreas Koster, et al.
Pageof 36